Cause and Prevention of Postoperative Acute Renal Failure in Patients with Malignant Tumors / 医学研究杂志

Objective To discuss the cause and means of prevention of postoperative acute renal failure(ARF) in patients with malignant tumors.Methods Clinical data of 32 patients with malignant tumors who suffered postoperative ARF were retrospectively studied.Results 13 patients(40.6%)suffered ARF because of hemorrhea or hypovolemia shock in or after operation, 10 patients(31.3%)suffered ARF because of fistula or sepsis after operation, 2 patients(6.3%)because of chemotherapy and other 7 patients(21.9%)with no evident causes. Conclusions ARF is a severe postoperative complication with high mortality. Maintaining adequate circulating volume before operation, carefully operating to decrease complication, avoiding nephrotoxins are key strategies to prevent the patients from ARF and improve prognosis.

Prognosis of primary liver carcinoma treated with local resection / 中华医学杂志(英文版)

<p><b>OBJECTIVE</b>To discuss the prognosis of primary liver carcinoma treated with local resection and factors affecting prognosis.</p><p><b>METHODS</b>The data of 130 patients who had been treated from October 1989 to October 1995 were analyzed retrospectively. We analyzed the concrete operating methods, the cause of postoperative complications and factors affecting prognosis.</p><p><b>RESULTS</b>Curative local resection was performed in 130 patients. Operation-related mortality was 0.8% and the incidence of complication was 16.1% (n = 18). The overall 1-, 3- and 5-year survival rates were 82.1%, 60.6% and 48.2%, respectively. Involvement of blood vessels or liver capsules and the elevation of AST before operation were the significant factors affecting prognosis (P < 0.05).</p><p><b>CONCLUSION</b>Local resection is a safe method characterized by little damage, rapid, less blood loss, low complication rate and good prognosis.</p>

Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma / 中华医学杂志(英文版)

<p><b>OBJECTIVES</b>To determine the pre-therapeutic serum level of vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma (HCC) and to elucidate the relation between the serum level and clinical characteristics and metastasis of HCC.</p><p><b>METHODS</b>One-hundred and fifteen HCC patients, 40 patients with benign liver lesions, and 30 healthy control subjects were included in this study. The serum VEGF level was measured with the quantitative sandwich enzyme linked immunosorbent assay (ELISA, R&D systems).</p><p><b>RESULTS</b>The serum VEGF levels in the HCC group (465.62 +/- 336.24 pg/ml) was significantly elevated as compared with those in patients with benign liver lesions (159.54 +/- 120.58 pg/ml) and those in normal controls (123.53 +/- 51.84 pg/ml). The VEGF levels were not significantly different between the patients with benign liver lesions and the normal controls. The serum VEGF levels showed a positive rate of 77.4%, 25%, and 3.3% in the HCC patients, benign liver lesion patients and normal controls, respectively. In the 115 HCC patients, the serum VEGF levels in patients with portal vein (PV) emboli (n = 26, 582.76 +/- 441.89 pg/ml), with metastasis (n = 43, 548.29 +/- 438.57 pg/ml) or with large HCC lesions (>/= 5 cm in diameter) (n = 69, 554.43 +/- 369.99 pg/ml) were significantly higher than those without PV-emboli (n = 89, 431.39 +/- 292.84 pg/ml), without metastasis (n = 72, 416.24 +/- 247.27 pg/ml) or with small HCC lesions (n = 42, 328.67 +/- 227.47 pg/ml). The serum VEGF levels in stage I, II, III, IVa and IVb HCC patients were 340.6 pg/ml, 451.55 +/- 307.84 pg/ml, 397.44 +/- 257.18 pg/ml, 486.10 +/- 397.73 pg/ml and 647.93 +/- 344.56 pg/ml, respectively.</p><p><b>CONCLUSION</b>The pre-therapeutic serum VEGF levels in HCC patients appear to reflect the disease's potential activity of vascular invasion and metastasis.</p>

Establishment of a sandwich ELISA method for detection of matrix metalloproteinase 9 protein in sera samples and preliminary application for hepatocellular carcinoma patients / 中华检验医学杂志

Objective Expression of recombinant human matrix metalloproteinase 9 (MMP9) protein in E coli,To establish a sandwich ELISA method for detecting MMP9 in sera and analyses of the difference of serum MMP9 in health population and the patient with hepatocellular carcinoma (HCC). Methods A fragment MMP9 sequence from nt 721-1 156 was amplified with PCR from the synthesized cDNAs of human liver tissues and inserted into the prokaryotic-expression plasmid pQE30.HIS-MMP9 fusion protein was expressed and purified from E coli MIS cells.The specific antibodies were elicited in rabbits and guinea pigs by immunization of the purified HIS-MMP9.After purifing antibodies with CNBr-activated Sepharose 4B,a sandwich ELISA technique was established.The serum MMP9 proteins were evaluated in 227 health adults and 193 HCC patients.Results SDS-PAGE displayed that the molecular-weight of the expressed fusion protein was about 17 000.The prepared antisera were able to recognize both recombinant and endogenously expressed MMP9 from human neutrophil and HepG2 cells.It was found that the average level of MMP9 proteins in HCC patients was higher than that in health control,showing significantly statistic difference.Conclusions The established method could reflect the level of serum MMPg.The data in this study supply scientific basis of generating methodology for screening metastasis and reoccurrence of HCC, using serum MMP9 as index.